Compositions and methods for targeting cancer-specific...

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S300000, C424S130100, C514S002600, C435S007100

Reexamination Certificate

active

07973135

ABSTRACT:
The invention provides molecules that target cancer-specific transcription complexes (CSTC), compositions and kits comprising CSTC-targeting molecules, and methods of using CSTC-targeting molecules for the treatment) detection and monitoring of cancer.

REFERENCES:
patent: 6248520 (2001-06-01), Roeder et al.
patent: 6268173 (2001-07-01), Chambon et al.
patent: 6380373 (2002-04-01), O'Malley
patent: 6586185 (2003-07-01), Wolf et al.
patent: 6861508 (2005-03-01), Chambon et al.
patent: 6965850 (2005-11-01), Baxter et al.
patent: 2003/0228607 (2003-12-01), Wagner et al.
patent: 2004/0031072 (2004-02-01), La Rosa et al.
patent: 2004/0214272 (2004-10-01), La Rosa et al.
patent: 2004/0219575 (2004-11-01), Neuman et al.
patent: 2005/0202440 (2005-09-01), Fletterick et al.
patent: 2003/000270 (2003-01-01), None
patent: WO 99/60014 (1999-11-01), None
patent: WO 2000/001820 (2000-01-01), None
patent: WO 02/02488 (2002-01-01), None
patent: WO 02/40716 (2002-05-01), None
patent: WO 02/095652 (2002-11-01), None
patent: WO 03/033515 (2003-04-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Onate, S.A., et al., “The Steroid Receptor Coactivator-1 Contains Multiple . . . Receptors”, J of Biological Chemistry, vol. 273, No. 20, May 15, 1998, pp. 12101-12108.
Ding, X.F. et al., “Nuclear Receptor-Bonding Sites of Coactivators . . . Specificities”, Mol. Endocrinol., vol. 12(2):302-313, Feb. 1998.
Flajollet, S. et al., “Distinct Roles of the Steroid Receptor Coactivator 1 . . . Differentiation”, J. of Biological Chemistry, 281(29):20338-20348, Jul. 2006.
Giangrande, P. et al., “The Opposing Transcriptional Activities of the Two Isoforms . . . Binding”, Molecular & Cellular Biology, 20(9):3102-3115, May 2000.
Wu, J. et al., Repression of p65 Transciptional Activation . . . Receptor, Molecular Endocrinology, 18(1):53-62, Jan 2004. (Abstract & result of sequence search).
Scarabel, L, Molecular Basis and Genetic Characterisation of Evolved . . . Rhoeas, Plant Science, 166:703-709, 2004, (Abstract & result of sequence search).
European Patent Office Search Report dated Dec. 23, 2009 from corresponding EP Patent Application No. 07812873.3.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compositions and methods for targeting cancer-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for targeting cancer-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for targeting cancer-specific... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2673809

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.